|Systematic (IUPAC) name|
|(what is this?)|
para-Methoxyamphetamine (PMA; "Death", "Dr. Death"), also known as 4-methoxyamphetamine (4-MA), is a serotonergic drug of the amphetamine class. Unlike other similar drugs of this family, PMA does not produce stimulant, euphoriant, or entactogen effects, and behaves more like an antidepressant in comparison, though it does have some psychedelic properties.
PMA has been found in tablets touted as MDMA (colloquially known as "ecstasy"), although its effects are markedly different compared to those of MDMA. The consequences of such deception has often been hospitalizations and deaths among unwitting users. PMA is commonly synthesized from anethole, the flavor compound of anise and fennel, mainly because the starting material for MDMA, safrole, has become less available due to law enforcement action, causing illicit drug manufacturers to use anethole as an alternative.
PMA first came into circulation in the early 1970s, where it was used intentionally as a substitute for the hallucinogenic properties of LSD. It went by the street names of "Chicken Powder" and "Chicken Yellow" and was found to be the cause of a number of drug overdose deaths (the dosages taken being in the range of hundreds of milligrams) in the United States and Canada from that time. Between 1974 and the mid-1990s, there appear to have been no known fatalities from PMA.
Several deaths reported as MDMA-induced in Australia in the mid-1990s are now considered to have been caused by PMA, the users unaware that they were ingesting PMA and not MDMA as they had intended. There have been a number of PMA-induced deaths around the world since then.
In July 2013, seven deaths in Scotland were linked to tablets containing PMA that had been mis-sold as ecstasy and which had the Rolex crown logo on them. Several deaths in Northern Ireland, Particularly East Belfast were also linked to "Green Rolex" pills during that month.
In 2014 and early 2015, PMA sold as ecstasy was attributed for more deaths in the United States, United Kingdom, and the Netherlands. The pills containing the drug were reported to be red triangular tablets with a "Superman" logo.
Because PMA is given out through the same venues and distribution channels that MDMA tablets are, the risk of being severely injured, hospitalized or even dying from use of ecstasy increases significantly when a batch of ecstasy pills containing PMA starts to be sold in a particular area. PMA pills could be a variety of colours or imprints, and there is no way of knowing just from the appearance of a pill what drug(s) it might contain. Notable batches of pills containing PMA have included Louis Vuitton, Mitsubishi Turbo, Blue Transformers, Red/Blue Mitsubishi and Yellow Euro pills. Also PMA has been found in powder form.
PMA acts as a selective serotonin releasing agent (SSRA) with weak effects on dopamine and norepinephrine transporters. However, relative to MDMA, it is considerably less effective as a releaser of serotonin with properties more akin to a reuptake inhibitor in comparison. It evokes robust hyperthermia in rodents while producing only modest hyperactivity and serotonergic neurotoxicity, substantially lower than that caused by MDMA, and only at very high doses. Accordingly, it is not self-administered by rodents unlike amphetamine and MDMA, and anecdotal reports by humans suggest it is not particularly euphoric at all, perhaps even dysphoric in contrast. PMA has also been shown to act as a potent, reversible inhibitor of the enzyme MAO-A with no significant effects on MAO-B, and the combination of this property and serotonin release is likely responsible for its high lethality potential.
It appears that PMA elevates body temperatures dramatically; the cause of this property is suspected to be related to its ability to inhibit MAO-A and at the same time releasing large amounts of serotonin, effectively causing serotonin syndrome. Amphetamines, especially serotonergic analogues such as MDMA, are strongly contraindicated to take with MAOIs. Many amphetamines and adrenergic compounds raise body temperatures; whereas some tend to produce more euphoric activity, or peripheral vasoconstriction, or tend to favor one effect over another, it appears that PMA activates the hypothalamus much more strongly than MDMA and other drugs like ephedrine, thereby causing rapid increases in body temperature (which is the major cause of death in PMA mortalities). Many people taking PMA try to get rid of the heat by taking off their clothes, taking cold showers or wrapping themselves in wet towels, and even sometimes by shaving off their hair.
PMA has been associated with numerous adverse reactions including death. Effects of PMA ingestion include many effects of the hallucinogenic amphetamines including accelerated and irregular heartbeat, blurred vision, and a strong feeling of intoxication that is often unpleasant. At high doses unpleasant effects such as nausea and vomiting, severe hyperthermia and hallucinations may occur. The effects of PMA also seem to be much more unpredictable and variable between individuals than those of MDMA, and sensitive individuals may die from a dose of PMA that a less susceptible person might only be mildly affected by. While PMA alone may cause significant toxicity, the combination of PMA with MDMA has a synergistic effect that seems to be particularly hazardous. Since PMA has a slow onset of effects, several deaths have occurred where individuals have taken a pill containing PMA, followed by a pill containing MDMA some time afterwards due to thinking that the first pill was not active.
Treatment of overdose
PMA overdose can be a serious medical emergency that may occur at only slightly above the usual recreational dose range, especially if PMA is mixed with other stimulant drugs such as cocaine or MDMA. Characteristic symptoms are pronounced hyperthermia, tachycardia, and hypertension, along with agitation, confusion, and convulsions. PMA overdose also tends to cause hypoglycaemia and hyperkalaemia, which can help to distinguish it from MDMA overdose. Complications can sometimes include more serious symptoms such as rhabdomyolysis and cerebral hemorrhage, requiring emergency surgery. There is no specific antidote, so treatment is symptomatic, and usually includes both external cooling, and internal cooling via IV infusion of cooled saline. Benzodiazepines are used initially to control convulsions, with stronger anticonvulsants such as phenytoin or thiopental used if convulsions continue. Blood pressure can be lowered either with a combination of alpha blockers and beta blockers (or a mixed alpha/beta blocker), or with other drugs such as nifedipine or nitroprusside. Serotonin antagonists and dantrolene may be used as required. Despite the seriousness of the condition, the majority of patients survive if treatment is given in time, however, patients with a core body temperature over 40°C at presentation tend to have a poor prognosis.
Four analogues of PMA have been reported to be sold on the black market, including PMMA, PMEA, 4-ETA and 4-MTA. These are the N-methyl, N-ethyl, 4-ethoxy and 4-methylthio analogues of PMA, respectively. PMMA and PMEA are anecdotally weaker, more "ecstasy-like" and somewhat less dangerous than PMA itself, but can still produce nausea and hyperthermia similar to that produced by PMA, albeit at slightly higher doses. 4-EtOA was briefly sold in Canada in the 1970s, but little is known about it. 4-MTA, however, is even more dangerous than PMA and produces strong serotonergic effects and intense hyperthermia, but with little to no euphoria, and was implicated in several deaths in the late 1990s.
- 1-Aminomethyl-5-methoxyindane (AMMI)
- 2-Methoxyamphetamine (OMA)
- 3-Methoxyamphetamine (MMA)
- 4-Methylamphetamine (4-MA)
- 4-Ethoxyamphetamine (4-ETA)
- 4-Methylthioamphetamine (4-MTA)
- 4-Methoxy-N-ethylamphetamine (PMEA)
- 4-Methoxy-N-methylamphetamine (PMMA)
- Ann Shulgin; Alexander Shulgin (1991). Pihkal: A Chemical Love Story. Transform Press. ISBN 0-9630096-0-5.
- Salna, Karlis (7 April 2008). "Warning of possible shift to killer drug". Sydney Morning Herald (Fairfax). Retrieved 2008-06-29.
- Corrigall WA, Robertson JM, Coen KM, Lodge BA (January 1992). "The reinforcing and discriminative stimulus properties of para-ethoxy- and para-methoxyamphetamine". Pharmacology, Biochemistry, and Behavior 41 (1): 165–9. doi:10.1016/0091-3057(92)90077-S. PMID 1539067.
- Hegadoren KM, Martin-Iverson MT, Baker GB (April 1995). "Comparative behavioural and neurochemical studies with a psychomotor stimulant, a hallucinogen and 3,4-methylenedioxy analogues of amphetamine". Psychopharmacology 118 (3): 295–304. doi:10.1007/BF02245958. PMID 7617822.
- Winter JC (February 1984). "The stimulus properties of para-methoxyamphetamine: a nonessential serotonergic component". Pharmacology, Biochemistry, and Behavior 20 (2): 201–3. doi:10.1016/0091-3057(84)90242-9. PMID 6546992.
- EcstasyData.org PMA results
- Davies, Caroline (10 July 2013). "Warning over fake ecstasy tablets after seven people die in Scotland". The Guardian. Retrieved 10 July 2013.
- Byard, RW; Gilbert, J; James, R; Lokan, RJ (1998). "Amphetamine Derivative Fatalities in South Australia-Is "Ecstasy" the Culprit?". The American Journal of Forensic Medicine and Pathology 19 (3): 261–265. doi:10.1097/00000433-199809000-00013. PMID 9760094. Retrieved 2008-06-29.
- Waumas D, Bruneel N, Tytgat J. Anise oil as para-methoxyamphetamine (PMA) precursor. Forensic Science International. 2003 Apr 23;133(1-2):159-70.
- "PiHKAL - #97 4-MA". www.erowid.org. Retrieved 1 September 2009.
- DEA. "The Hallucinogen PMA: Dancing With Death" (PDF). Retrieved 2008-06-29.
- Felgate, Heather E.; Felgate, Peter D.; James, Ross A.; Sims, Noel; Vozzo, Dominic C. (1998). "Recent Paramethoxyamphetamine Deaths". Journal of Analytical Toxicology 22 (2): 169–172. doi:10.1093/jat/22.2.169. PMID 9547415. Retrieved 2008-06-29.
A Canadian report from 1974 is the most recent report of death due to PMA toxicity
- Galloway JH, Forrest AR (September 2002). "Caveat Emptor: Death involving the use of 4-methoxyamphetamine". Journal of Clinical Forensic Medicine 9 (3): 160. doi:10.1016/S1353-1131(02)00043-3. PMID 15274949.
- Lamberth PG, Ding GK, Nurmi LA (April 2008). "Fatal paramethoxy-amphetamine (PMA) poisoning in the Australian Capital Territory". The Medical Journal of Australia 188 (7): 426. PMID 18393753.
- Galloway JH, Forrest AR. Caveat Emptor: Death involving the use of 4-methoxyamphetamine. Journal of Clinical Forensic Medicine. 2002 Sep;9(3):160.
- "Drug Info". Archived from the original on 2008-05-29. Retrieved 2008-06-15.
- "Warning: pills sold as ecstasy found to contain PMA". Retrieved 2008-06-15.
- Chamberlin T, Murray D. NET Syndicated QLD News 'Louis Vuitton' designer death drug hits the streets
- Kraner JC, McCoy DJ, Evans MA, Evans LE, Sweeney BJ. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). Journal of Analytical Toxicology. 2001 Oct;25(7):645-8.
- Menon MK, Tseng LF, Loh HH (May 1976). "Pharmacological evidence for the central serotonergic effects of monomethoxyamphetamines". The Journal of Pharmacology and Experimental Therapeutics 197 (2): 272–9. PMID 946817.
- Hitzemann RJ, Loh HH, Domino EF (October 1971). "Effect of para-methoxyamphetamine on catecholamine metabolism in the mouse brain". Life Sciences. Pt. 1: Physiology and Pharmacology 10 (19): 1087–95. doi:10.1016/0024-3205(71)90227-x. PMID 5132700.
- Tseng LF, Menon MK, Loh HH (May 1976). "Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue". The Journal of Pharmacology and Experimental Therapeutics 197 (2): 263–71. PMID 1271280.
- Daws LC, Irvine RJ, Callaghan PD, Toop NP, White JM, Bochner F (August 2000). "Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat". Progress in Neuro-psychopharmacology & Biological Psychiatry 24 (6): 955–77. doi:10.1016/S0278-5846(00)00113-5. PMID 11041537.
- Green AL, El Hait MA (April 1980). "p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo". The Journal of Pharmacy and Pharmacology 32 (4): 262–6. doi:10.1111/j.2042-7158.1980.tb12909.x. PMID 6103055.
- Ask AL, Fagervall I, Ross SB (September 1983). "Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain". Naunyn-Schmiedeberg's Archives of Pharmacology 324 (2): 79–87. doi:10.1007/BF00497011. PMID 6646243.
- Selective inhibition of monoamine oxidase in monoa...[Naunyn Schmiedebergs Arch Pharmacol. 1983] - PubMed Result
- Jaehne EJ, Salem A, Irvine RJ. Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation. Pharmacology Biochemistry and Behavior. 2005 Jul;81(3):485-96.
- Callaghan PD, Irvine RJ, Daws LC. Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry. Neurochemistry International. 2005 Oct;47(5):350-61.
- Jaehne EJ, Salem A, Irvine RJ. Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. Psychopharmacology (Berlin). 2007 May 27
- Refstad S. Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects. Acta Anaesthesiologica Scandinavia. 2003 Nov;47(10):1298-9.
- Martin TL. Three cases of fatal paramethoxyamphetamine overdose. Journal of Analytical Toxicology. 2001 Oct;25(7):649-51.
- Becker J, Neis P, Röhrich J, Zörntlein S. A fatal paramethoxymethamphetamine intoxication. Legal Medicine (Tokyo). 2003 Mar;5 Suppl 1:S138-41.
- Smets G, Bronselaer K, De Munnynck K, De Feyter K, Van de Voorde W, Sabbe M. Amphetamine toxicity in the emergency department. European Journal of Emergency Medicine. 2005 Aug;12(4):193-7.
- Lora-Tamayo C, Tena T, Rodriguez A, Moreno D, Sancho JR, Ensenat P, Muela F. The designer drug situation in Ibiza. Forensic Science International. 2004 Mar 10;140(2-3):195-206.
- Dams R, De Letter EA, Mortier KA, Cordonnier JA, Lambert WE, Piette MH, Van Calenbergh S, De Leenheer AP. Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study. Journal of Analytical Toxicology. 2003 Jul-Aug;27(5):318-22.
- Caldicott DG, Edwards NA, Kruys A, Kirkbride KP, Sims DN, Byard RW, Prior M, Irvine RJ (2003). "Dancing with "death": p-methoxyamphetamine overdose and its acute management". Journal of Toxicology. Clinical Toxicology 41 (2): 143–54. doi:10.1081/CLT-120019130. PMID 12733852.
- John F. Casale, Patrick A. Hays, Trinette K. Spratley, and Pamela R. Smith. The Characterization of 4-Methoxy-N-ethylamphetamine Hydrochloride. DEA Microgram Journal 2006; 4(1-4)
- Alexander & Ann Shulgin, PiHKAL #97
- "Annual Estimates Of Requirements Of Narcotic Drugs, Manufacture Of Synthetic Drugs, Opium Production And Cultivation Of The..." (PDF). Retrieved 2008-06-15.
- "Doden na gebruik speed met 4-MA" [Deaths after using speed 4-MA] (in Dutch). 13 June 2012.
- PiHKAL PMA entry
- PMA entry in PiHKAL • info
- The Hallucinogen PMA: Dancing With Death (in PDF format) from the Drug Enforcement Administration
- Death drug may become health crisis, news.ninemsn.com.au article, Issued 22 February 2007.